PURPOSE: To investigate whether magnetic resonance imaging (MRI) is superior to clinical palpation in the assessment of response of breast cancer to primary chemotherapy (PC). PATIENTS AND METHODS: Seventy-three patients with T2-4, N0, M0 breast cancer were treated with 3-4 cycles of single agent epirubicin before definitive surgery. MRI was performed at baseline condition and at the end of chemotherapy. RESULTS: According to the WHO criteria, 20 (27.4%) patients attained a complete response (CR) by clinical palpation and 41 (56.2%) a partial response. The corresponding response rate by MRI was 11 (15.1%) and 34 (46.6%), respectively. Residual tumor assessed by MRI better correlated with pathologic measurements (Spearman r : 0.72) than residual tumor assessed by clinical palpation (Spearman r : 0.58). Post-chemotherapy histology evaluation revealed pathologic CR in three cases, only one of them was considered as complete responder by MRI. Residual disease consisted in in situ carcinoma in four cases, one of them was complete responder at MRI, the remaining three showed residual abnormal contrast enhancement indistinguishable from that of invasive tumors. CONCLUSIONS: As compared to pathology specimens, MRI is able to represent the extent of cancer more accurately than clinical palpation. It constitutes a promising technique in assessing the BC response to PC. The current limit of MRI is the scarce specificity in predicting the nature of residual disease. Copyright 2004 Kluwer Academic Publishers
PURPOSE: To investigate whether magnetic resonance imaging (MRI) is superior to clinical palpation in the assessment of response of breast cancer to primary chemotherapy (PC). PATIENTS AND METHODS: Seventy-three patients with T2-4, N0, M0 breast cancer were treated with 3-4 cycles of single agent epirubicin before definitive surgery. MRI was performed at baseline condition and at the end of chemotherapy. RESULTS: According to the WHO criteria, 20 (27.4%) patients attained a complete response (CR) by clinical palpation and 41 (56.2%) a partial response. The corresponding response rate by MRI was 11 (15.1%) and 34 (46.6%), respectively. Residual tumor assessed by MRI better correlated with pathologic measurements (Spearman r : 0.72) than residual tumor assessed by clinical palpation (Spearman r : 0.58). Post-chemotherapy histology evaluation revealed pathologic CR in three cases, only one of them was considered as complete responder by MRI. Residual disease consisted in in situ carcinoma in four cases, one of them was complete responder at MRI, the remaining three showed residual abnormal contrast enhancement indistinguishable from that of invasive tumors. CONCLUSIONS: As compared to pathology specimens, MRI is able to represent the extent of cancer more accurately than clinical palpation. It constitutes a promising technique in assessing the BC response to PC. The current limit of MRI is the scarce specificity in predicting the nature of residual disease. Copyright 2004 Kluwer Academic Publishers
Authors: Jeon-Hor Chen; Byron A Feig; David J-B Hsiang; John A Butler; Rita S Mehta; Shadfar Bahri; Orhan Nalcioglu; Min-Ying Su Journal: Ann Surg Date: 2009-03 Impact factor: 12.969
Authors: L Bazzola; C Foroni; D Andreis; V Zanoni; M R Cappelletti; G Allevi; S Aguggini; C Strina; M Milani; S Venturini; F Ferrozzi; R Giardini; R Bertoni; H Turley; K Gatter; P G Petronini; S B Fox; A L Harris; M Martinotti; A Berruti; A Bottini; A R Reynolds; D Generali Journal: Br J Cancer Date: 2014-12-02 Impact factor: 7.640
Authors: Claudette E Loo; Lisanne S Rigter; Kenneth E Pengel; Jelle Wesseling; Sjoerd Rodenhuis; Marie-Jeanne T F D Vrancken Peeters; Karolina Sikorska; Kenneth G A Gilhuijs Journal: Breast Cancer Res Date: 2016-08-05 Impact factor: 6.466
Authors: Michael L Marinovich; Petra Macaskill; Les Irwig; Francesco Sardanelli; Eleftherios Mamounas; Gunter von Minckwitz; Valentina Guarneri; Savannah C Partridge; Frances C Wright; Jae Hyuck Choi; Madhumita Bhattacharyya; Laura Martincich; Eren Yeh; Viviana Londero; Nehmat Houssami Journal: BMC Cancer Date: 2015-10-08 Impact factor: 4.430
Authors: M L Marinovich; P Macaskill; L Irwig; F Sardanelli; G von Minckwitz; E Mamounas; M Brennan; S Ciatto; N Houssami Journal: Br J Cancer Date: 2013-08-20 Impact factor: 7.640